Loss of park7 activity has differential effects on expression of iron responsive element (IRE) gene sets in the brain transcriptome in a zebrafish model of Parkinson’s disease

Mutation of the gene PARK7 (DJ1) causes monogenic autosomal recessive Parkinson’s disease (PD) in humans. Subsequent alterations of PARK7 protein function lead to mitochondrial dysfunction, a major element in PD pathology. Homozygous mutants for the PARK7-orthologous genes in zebrafish, park7, show changes to gene expression in the oxidative phosphorylation pathway, supporting that disruption of energy production is a key feature of neurodegeneration in PD. Iron is critical for normal mitochondrial function, and we have previously used bioinformatic analysis of IRE-bearing transcripts in brain transcriptomes to find evidence supporting the existence of iron dyshomeostasis in Alzheimer’s disease. Here, we analysed IRE-bearing transcripts in the transcriptome data from homozygous park7−/− mutant zebrafish brains. We found that the set of genes with “high quality” IREs in their 5′ untranslated regions (UTRs, the HQ5′IRE gene set) was significantly altered in these 4-month-old park7−/− brains. However, sets of genes with IREs in their 3′ UTRs appeared unaffected. The effects on HQ5′IRE genes are possibly driven by iron dyshomeostasis and/or oxidative stress, but illuminate the existence of currently unknown mechanisms with differential overall effects on 5′ and 3′ IREs. Supplementary Information The online version contains supplementary material available at 10.1186/s13041-021-00792-9.


Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting approximately 1% of the population aged over 60 years. Most cases of PD are idiopathic, but a clear genetic link has been identified in approximately 5-10% of PD cases [1]. One gene, PARK7, implicated in autosomal recessive early-onset PD, encodes Parkinson disease protein 7 (PARK7). PARK7 protein has been suggested to act as a GSH-independent glyoxalase for detoxification of methylglyoxal and as a protein glycase responsible for restoring the function of proteins damaged by oxidative stress. However, these activities are disputed in PD (reviewed and analysed in [2]). PARK7 also has critical roles in maintaining mitochondrial function, sensing and responding to reactive oxygen species (ROS), and ultimately, acts in neuroprotection (reviewed in [3]).
PD is characterized by the specific depletion of substantia nigra pars compacta dopaminergic (SNc DA) neurons. These neurons make large numbers of synapses in the basal ganglia. Consequently, their high energy demands may make SNc DA neurons sensitive to energy deficiency [4]. Many factors can affect energy production by the process of oxidative phosphorylation. In particular, ferrous iron (Fe 2+ ) is incorporated into Fe-S clusters central Open Access *Correspondence: karissa.barthelson@adelaide.edu.au 1 Alzheimer's Disease Genetics Laboratory, School of Biological Sciences, University of Adelaide, North Terrace, Adelaide, SA 5005, Australia Full list of author information is available at the end of the article to the function of the electron transport chain (ETC) in oxidative phosphorylation [5]. ETC dysfunction causes oxidative stress that may lead to the (primarily) cytosolic PARK7 protein translocating into mitochondria to regulate the effects of reactive oxygen species (ROS) [5]. This process is possibly altered in individuals with mutation of PARK7, leading to ETC dysfunction and dyshomeostasis of iron (via effects on Iron Regulatory Proteins, IRP1 & IRP2) and damaging dopaminergic neurons.
IRP1 and IRP2 bind IREs in the mRNAs of genes involved in iron homeostasis to regulate their translation and stability (reviewed in [6]). IRPs are regulated both by cellular ferrous iron status and oxidative stress [6]. Previously, we defined sets of genes bearing IREs in either the 5′ or 3′UTRs of their transcripts (at lower or higher similarity to an IRE consensus sequence) in humans, mice and zebrafish [7]. Using these, we found evidence supporting iron dyshomeostasis in Alzheimer's disease (AD) brains, and in animal models of AD [7].
Orthologues of PD genes have previously been identified and manipulated in zebrafish. For example, Hughes et al. [8] developed a novel zebrafish model to examine the function of PARK7. Zebrafish which lack the PARK7orthologous gene: park7 (park7 −/− ) display a movement phenotype at three months of age, and show changes to gene expression in their brain transcriptome suggestive of disrupted mitochondrial metabolism (i.e., upregulation of genes associated with oxidative phosphorylation) at four months of age [8]. Therefore, we hypothesized that oxidative stress and/or iron dyshomeostasis in park7 −/− zebrafish brains would alter binding of IRPs to transcripts containing IREs, thereby altering transcript stability. To explore this, we reanalysed the zebrafish brain transcriptome data from Hughes et al. to test for changes in the representation of IRE-containing gene sets in park7 −/− zebrafish brains. We found that the HQ5′IRE gene set is significantly altered in 4-month-old park7 −/− brains, while the HQ3′IRE gene set is not.

Methods
To test for evidence of possible iron dyshomeostasis in park7 −/− zebrafish brains, we performed enrichment analysis using fry [9] on the IRE gene sets [7]. For detailed information of this re-analysis of Hughes et al. [8] data, see Additional file 1.

Results
We previously defined sets of zebrafish genes according to whether these possess IRE-like motifs in either the 5′ or 3′ UTRs of their mRNAs, and whether their IREs match a canonical (high quality, HQ) or noncanonical IRE sequence (all) [7]. We found that only transcripts of the HQ5'IRE gene set show statistically significant changes to gene expression as a group (Fig. 1a) in 4-month-old park7 −/− brains. Interestingly, the most upregulated gene of the HQ5'IRE gene set is alas2.

Discussion
Using our method to detect evidence for iron dyshomeostasis in RNA-seq data, we found highly significant alteration of the expression of genes with IREs in the 5'UTRs of their mRNAs in 4-month-old park7 −/− brains. Iron homeostasis is maintained by regulation of gene expression at several levels, including via transcription, mRNA stability, and mRNA translation (reviewed in [10]). The latter two phenomena are modulated by the iron regulatory proteins IRP1 and IRP2 when these bind to IREs. The highly significant alteration of expression of the HQ5′IRE gene set in 4-month-old park7 −/− brains is likely due to changes in binding of IRP1 and/ or IRP2 to IREs in the transcripts of these genes. However, since mutation of PARK7 is known to cause oxidative stress [11] and oxidative stress can also affect IRP formation (reviewed in [6]), it is difficult to differentiate between oxidative stress and iron dyshomeostasis as contributing to changes in HQ5′IRE gene transcript abundance. Indeed, since iron is so important for mitochondrial function, iron dyshomeostasis and oxidative stress often co-occur [12]. Interestingly, the HQ3′IRE gene set appeared unaffected in park7 −/− brains and we currently have no explanation for why this should be so. However, if the effects on HQ5'IRE transcript abundance are, indeed, due to binding of IRPs, this points to the existence of mechanisms that can discriminate in binding of IRPs to IREs (or cause differences in the effects of such binding), depending on whether an IRE resides in the 5′ or 3′ UTR of a transcript.
Among members of the HQ5'IRE gene set, alas2 transcript levels were observed to be increased in park7 −/− brains. The relationship between alas2 activity and IRPs is discussed in Additional file 1.
Taken together, our analysis of transcriptome data from park7 −/− zebrafish brains supports the possibility of iron dyshomeostasis and/or oxidative stress as early preclinical events in PD. In future studies, we will explore the nature of the effects of PD-linked genes on iron homeostasis and mitochondrial function in zebrafish. Understanding these effects can provide mechanistic insight into PD for the development of therapeutics.